Contrast echocardiography: evidence for clinical use.
The failure of echocardiography to give diagnostically useful information in a significant proportion of patients has led to the development of specific contrast agents to enhance imaging. Suitable contrast media must have the ability to modify ultrasound characteristics, be capable of crossing the pulmonary capillary bed, show stability over the duration of a procedure, offer low blood solubility with low toxicity and be rapidly eliminated. The current generation of ultrasound contrast agents comprises microbubbles of a high molecular-weight gas encapsulated in a shell of phospholipid or protein. A review of the clinical evidence shows that these agents are clinically effective in enhancing echocardiographic imaging. They enable the rescue of failed procedures, often sparing patients from invasive tests, but appear not to add to the burden of side effects. Indeed, the benefits of using contrast agents in stress echocardiography have been recommended in recently published American Society of Echocardiography guidelines. Myocardial contrast echocardiography has now developed to the stage where assessment of myocardial perfusion for the detection of coronary artery disease is possible with the same diagnostic accuracy as radionuclide imaging. However, in comparison with the latter technique, it is less expensive, is more portable, and avoids the use of ionizing radiation. It is precisely the ability of myocardial contrast echocardiography to simultaneously assess function and perfusion at the bedside that has given it a unique role in clinical practice. This review provides an overview of the clinical evidence supporting the efficacy of contrast echocardiography in the assessment of myocardial structure, function, and perfusion.